Electoral roll changes led to frustration on polling day as Mumbai locals found their names deleted or shifted, forcing ...

Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline ...

The controversial housing plan has been a point of contention ever since it was first touted almost a decade ago ...

A controversial housing scheme that would change the face of Hyde ’s green space forever is due to be scrutinised again. The ...

While I believe Pfizer will rebound eventually, it will take some time to do so, and it may not occur in 2026. In the meantime, other healthcare leaders could perform significantly better this year ...

It's understood the writing was on the wall for the EU-Mercosur agreement not long after the meeting of EU ambassadors got ...

Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated a Buy rating on Pfizer Inc. (NYSE:PFE) on December 17 and set a price ...

Several corporate governance experts said the statements and omissions were in line with a broader fear among business ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

In the latest close session, Pfizer (PFE) was up +1.12% at $25.18. The stock outpaced the S&P 500's daily gain of 0.19%. Meanwhile, the Dow experienced a rise of 0.66%, and the technology-dominated ...